WJPR Citation New

  All Since 2019
 Citation  7475  4312
 h-index  28  21
 i10-index  197  83

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

LULICONAZOLE FOR THE TREATMENT OF FUNGAL INFECTIONS

Manoj Digambar Ingole*, Nitin Namdev Fating and Unnati T. Rathod

.

Abstract

Luliconazoleis an imidazole antifungal agent with a uniquestructure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole. In this review, we summarize the in vitro data, animal studies, and clinical trial data relating to the use of topical luliconazole. Luliconazole is a novel imidazole derivative, which has demonstrated in vitro efficacy against dermatophytes and Candida albicans. Preclinical studies have showed the excellent activity of luliconazole against dermatophytes and luliconazole shows the activity against Candida albicans. As per the clinical study luliconazole has strong antifungal activity and favourable pharmacokinetic properties in the skin. Clinical trials have demonstrated its superiority over placebo in dermatophytosis and its antifungal activity is better than terbinafine. A Phase I/II a study has shown excellent local tolerability and a lack of systemic side effects with use of topical luliconazole solution for onychomycosis. The Phase III study had shownthat luliconazole 1% cream also produced favourable clinical and mycological results in clinical trials for tinea corporis and tinea cruris. Luliconazole 1% cream was approved in Japan in 2005 for the treatment of tinea infections. Luliconazole is approved in the United States as a 1% topical cream for tinea corporis, tinea pedis and tinea cruris caused by T. rubrum. Topical luliconazole has a favourable safety profile, with only mild application site reactions reported occasionally. From this review article we concludeLuliconazole has more potent antifungal activity than Lanoconazole and Topical luliconazole has a favourable safety profile which shows anti dermatophyte activity and Effective therapy for the management of tinea corporis, tinea pedis and tinea crusis.

Keywords: Luliconazole, dermatophytosis, onychomycosis, clinical trials, review, tinea corporis, tinea pedis, topical luliconazole, antifungal agent, fungal infection.


[Full Text Article]  [Download Certificate]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More